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Abstract
Patients on warfarin are required to withdraw from treatment for a fixed period (normally 5 days) prior to an invasive pro-
cedure. However, the anticoagulant effect of warfarin subsides at different rates among different patients, exposing some 
to increased risk of either thrombosis or bleeding. In a recent study in patients awaiting surgery, following warfarin ces-
sation the INR declined slower over time in those with two CYP2C9 variant alleles, increasing age, weight and number of 
comorbidities and that INR decline was faster in those with higher maintenance INR value. Subsequently, we developed an 
algorithm which predicts INR decline in individual patients after 5 days of warfarin cessation. The current study validated 
the algorithm. An independent cohort of patients completing a short course of warfarin took part in the study. INR values 
for subsequent 9 days and CYP2C9 genotype were available. The predicted INR decline  (INRday 1–INRday 5) was compared 
to the observed one (where an INR check on day 5 was unavailable, INR was estimated using a linear approximation model). 
There was a strong correlation between the decline in INR by day 5 and that predicted from the algorithm for the 117 patients 
(r = 0.949, p < 0.001). The algorithm was precise, with low degree of bias and variance of the prediction error. The algorithm 
can accurately predict the INR decline following warfarin cessation in individual adult patients. The use of this easily adopt-
able algorithm can reduce cancellation or delays of planned surgical procedures.
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Highlights
• The effect of warfarin subsides at different rates among 
different patients based upon individual patient charac-
teristics.
• An algorithm predicting the fall in INR within 5 days in 
individual patients was validated.
• There was a strong and significant correlation between 
the observed and predicted fall in INR.
• The validated algorithm can accurately predict the fall in 
INR after warfarin cessation for individual patients and 
is easy to implement in clinic.
Introduction
Patients on warfarin are required to stop treatment for a 
fixed period (5 days according to local guidelines) prior to 
an invasive procedure, in order to minimise the risk of peri-
operative bleeding [1]. However, the anticoagulant activ-
ity of warfarin subsides at different rates among different 
patients, thus withholding warfarin for 5 days may not result 
in restoration of normal coagulation in all patients. Discon-
tinuation of therapy too early may predispose the patient to 
thrombosis or stopping it too late may result in cancella-
tion of the planned procedure due to risk of peri-operative 
bleeding.
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In a recent study in adult patients who interrupted warfa-
rin therapy prior to elective surgery, we demonstrated that 
the rate of INR decline following warfarin cessation was 
slower in patients with two CYP2C9 variant alleles, increas-
ing age, weight and number of comorbidities and faster with 
greater INR value prior to warfarin withdrawal. These fac-
tors accounted for approximately 90% of the inter-individual 
variability in the rate of INR decline [2]. Based upon the 
study results an algorithm was developed to predict the fall 
in INR in individual patients 5 days after warfarin cessation.
This study aimed to validate the algorithm, using data 
from an independent cohort of patients who had discontin-
ued warfarin therapy for a reason unrelated to surgery.
Patients, materials and methods
Study cohorts
The algorithm developed was derived by multiple regression 
analysis of data in a cohort of adult patients recruited as part 
of an earlier study [2] (designated as the algorithm cohort) 
as shown below:
where age in years; n.CYP2C9: presence of CYP2C9 double 
variant (either *3*3, *3*2, or *2*2) = 1 and absence of dou-
ble variant = 0, index INR (INR on day 1); w: weight in kg 
and n.com: number of comorbidities, including AF or other 
indication for warfarin therapy.
The inclusion and exclusion criteria of patients in the 
algorithm cohort have been previously reported [2].
Inclusion criteria for patients used to validate the algo-
rithm (designated as the validation cohort) were the ability 
to provide informed consent, age ≥ 18 years, and about to 
discontinue warfarin therapy. Patients were excluded if they 
were either taking any concurrent medication or had any 
chronic condition that may affect warfarin disposition or 
its pharmacologic activity, or excessive alcohol intake that 
could have affected anticoagulation response to warfarin.
Data analysis
Data belonging to an independent cohort of Caucasian 
patients aged ≥ 18 years, who had completed a course of 
warfarin, were available for the algorithm validation. Infor-
mation on demographics, clinical data, CYP2C9 genotype 
and INR value (measured in citrated plasma specimens) on 
the day of warfarin cessation and on alternate days for the 
following 9 days were available [3].
INR decline by day 5 = −0.195 − 0.00428 {age} − 0.2374 (n.CYP2C9) + 0.9143 {INR} − 0.00246 {w} − 0.0306 (n.com)
The accuracy of the algorithm was tested by assessing the 
correlation between the observed INR decline [calculated 
by subtracting the INR value on day 5 from the index INR 
value in the morning following warfarin cessation (day 1)] 
and the predicted decline in INR according to the algorithm. 
The performance of the algorithm was evaluated, according 
to the method of Sheiner and Beal [4], using the root mean 
squared prediction error (RMSE) as a measure of precision 
and the mean prediction error (ME) as a measure of bias. 
The mean squared deviation of prediction errors from their 
mean (mSDEM) was determined as an estimate of the vari-
ance of the prediction error.
The days of INR checks following warfarin cessation var-
ied among the validation cohort for scheduling purposes. 
For patients with an INR check on day 5 (± 10 h) the INR 
value was designated as the observed value. To determine 
the INR value on day 5 for those without an INR check 
on that day, a linear approximation model that assumes an 
exponential INR decline asymptotically over time was used 
as previously described by White and colleagues [5] with 
a further assumption that over time INR reaches a baseline 
value of 0.8 [6]. Transformation of INR into logarithm after 
subtracting the asymptote results in a linear model. The INR 
value on day 5 was derived from the plot of the natural loga-
rithm of INR-0.8 against time in hours following warfarin 
cessation.
Excel (Microsoft Corp., Redmond, WA, USA) was used 
for data collation and Minitab (Coventry, UK) was used for 
statistical analysis. Where necessary, data were transformed 
to achieve approximate normality. Demographic and clini-
cal data common to both cohorts were used for comparison. 
Unless otherwise stated, INR decline values are presented 
as mean (range).
Results
Of the 131 patients available in the validation cohort, 14 
were excluded from final analysis for the following reasons; 
7 had an index INR of 1.5 or lower, 2 had no index INR 
value recorded, 2 had data missing on at least two parameters 
included in the algorithm and 3 had their last recorded INR 
check > 40 h before day 5. Overall, 117 patients were avail-
able for analysis, with mean index INR value of 2.5. Demo-
graphics for both patient cohorts are presented in Table 1. 
Patients in the algorithm and validation cohorts were sig-
nificantly different in age (p < 0.001 for males and p = 0.002 
for females; Student’s t-test), mean warfarin weekly dose 
(p = 0.004 for males and p = 0.036 for females; Student’s 
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t-test) and indication for anticoagulation (p < 0.001; Chi 
square test).
All but one patients reached INR < 1.5 at day 5. A sin-
gle patient with INR = 1.6 at day 5, which was a predicted 
value through the linear approximation model in the absence 
of an INR check close to day 5, was a 71-year old female, 
weighing 94 kg, with index INR of 2.3, 2 comorbidities and 
carrying one variant CYP2C9 allele.
Seventy patients had an INR check on day 5 (± 10 h). The 
observed INR on day 5 was 1.1 (0.9–1.4). The decline in the 
observed INR value (i.e. INR on day 1 − INR on day 5) was 
1.4 (0.4–3.5) while the algorithm predicted a decline in INR 
of 1.6 (0.9–3.4). The actual and predicted INR declines were 
strongly and significantly correlated (r = 0.969, p < 0.001; 
Pearson test).
To confirm the accuracy of the linear approximation 
model the INR value on day 5 was estimated according to 
the model, as explained earlier, and the estimated INR values 
were compared to the actual values in the above subgroup 
of patients. There was a very strong and highly significant 
Table 1  Patient demographics 
for the algorithm and validation 
cohorts
a Based on 112 patients
b The reported number of comorbidities includes indication for anticoagulation and the number of concomi-
tant medications includes warfarin
c Based on 116 patients
d Based on 115 patients
e Based on 140 patients
f Student’s t-test
g Chi squared test
Algorithm cohort Validation cohort p value
No of patients 152 117
Sex, n (%) g
 Male 102 (67) 65 (55.6) 0.053
 Female 50 (33) 52 (44.4)
Age (years), mean (range) a f
 Male 74 (43–90) 63 (29–92) < 0.001
 Female 72 (49–93) 64 (21–88) 0.002
Height (cm), mean ± SD e c f
 Male 174 ± 9 176 ± 7 0.052
 Female 160 ± 5 161 ± 8 0.224
Weight (kg), mean ± SD c f
 Male 88 ± 17 92 ± 20.3 0.081
 Female 81 ± 19 81 ± 22.6 1.000
Warfarin weekly dose (mg), mean ± SD d f
 Male 28.7 ± 10.3 34.9 ± 15.0 0.004
 Female 27.4 ± 14.0 33.4 ± 14.5 0.036
Indication for anticoagulation, n (%) g
 Atrial fibrillation 125 (82) 12 (10.3) < 0.001
 Venous thromboembolism 27 (18) 63 (53.8)
 Pulmonary embolism 0 33 (28.2)
 Other 0 9 (7.7)
No of comorbidities, mean (range)b 3 (1–8) 2 (1–6)c < 0.001
No of concomitant medications, mean (range) 5 (1–12) 5 (1–15) 0.093
CYP2C9 genotype d g
 *1/*1 92 64 0.553
 *1/*2 35 31
 *1/*3 15 14
 *2/*2 4 5
 *2/*3 6 1
 *3/*3 0 0
Index INR mean ± SD (range) – 2.5 ± 0.6 (1.6–4.5)
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correlation (r = 0.905, p < 0.001; Spearman test, Fig. 1) 
between the actual INR and estimated INR values, with a 
maximum difference in INR of 0.2 units, which is not clini-
cally significant.
For 47 patients INR check on day 5 was not recorded. 
Therefore, INR on day 5 was estimated using the linear 
approximation model, with a mean of 1.1 (0.9–1.6) and 
a decline in INR (INR on day 1–INR on day 5) of 1.3 
(0.5–3.3). Based on the algorithm, the predicted decline in 
INR is 1.5 (0.6–3.3). There was a strong and highly signifi-
cant correlation between the decline in the INR derived from 
the model and that predicted from the algorithm (r = 0.932, 
p < 0.001; Spearman test).
Overall, there was a strong and highly significant cor-
relation between the decline in INR by day 5 (based on both 
actual INR value and that predicted from the linear approxi-
mation model) and that predicted from the algorithm for the 
whole cohort of 117 patients (r = 0.949, p < 0.001; Spear-
man test, Fig. 2). The RMSE was 0.22, indicating that the 
algorithm was precise at 0.22 units of INR decline. The ME 
was 0.15 and the mSDEM was 0.026, which confirm the low 
degree of bias and variance of the prediction error.
Fig. 1  Actual INR value on day 
5 following warfarin cessation 
versus INR value obtained from 
linear regression slope (n = 70)
Fig. 2  Predicted versus 
observed change in INR (day 
1–day 5)
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Of the whole validation cohort, only 6 patients (5.1%) 
had double variant CYP2C9 genotype which is consistent 
with the observed low frequency of this genotype in the 
Caucasian population [7]. Removing the effect of genotype 
from the algorithm resulted in an increase of 0.2 units in 
the predicted INR decline for these patients [0.1 (0.0–0.2)]. 
Overall, for all 117 patients and after removing the effect of 
genotype from the algorithm, there was a strong and highly 
significant correlation between the observed and predicted 
decline in INR (r = 0.958, p < 0.001; Spearman test) and 
equal predictive performance (RMSE = 0.22, ME = 0.16 and 
mSDEM = 0.022).
For greater ease of use, the algorithm can be transformed 
to a more simplified version as follows:
where INR; index INR, N.CYP2C9; the presence of 
CYP2C9 double variant (either *3*3, *3*2, or *2*2) = 1 
and absence of double variant = 0, AGE; age in years, W; 
weight in kg, N.COM; number of comorbidities.
This simplified algorithm has comparable accuracy to the 
original algorithm in terms of high precision (RMSE = 0.19), 
low degree of bias (ME = 0.11) and small variance of the 
prediction error (mSDEM = 0.026).
Discussion
Approximately 1 in 6 patients per year treated with warfarin 
undergo invasive surgical procedure and are required to dis-
continue treatment prior to the event [8]. In order to minimize 
the risk of perioperative bleeding, guidelines suggest that war-
farin therapy is stopped 5 days before an invasive procedure [1, 
9–11]. This recommendation is based upon the estimated war-
farin clearance and the rate of production of functional coagula-
tion factors II and X after the withdrawal of warfarin treatment 
[12]. However, a significant proportion of patients awaiting 
surgery remain above the INR threshold of 1.5 five days after 
the cessation of warfarin therapy [5, 13, 14] which necessitates 
the cancellation or delay of the planned procedure. This can be 
costly to healthcare providers and inconvenient to the patient.
An accurate method of predicting INR decline in individual 
patients is particularly useful for those with extreme demo-
graphics and in frail older patients with many comorbidities 
and other physiological factors that affect normal coagulation, 
who may present with therapeutic INR on the day of surgery 
[15, 16]. Accurate prediction of INR is also relevant for people 
withdrawing from warfarin with the aim of switching to treat-
ment with DOACs, in which case there is specific threshold 
of INR value below which the transitioning to a DOAC can 
be performed (when INR is ≤ 3.0 for rivaroxaban, ≤ 2.5 for 
edoxaban, and ≤ 2.0 for apixaban and dabigatran) [17].
INR decline by day 5 = 0.9 {INR} − 0.2 {N.CYP2C9} − 0.2 − [13 {AGE} + 7.4 {W} + 92 {N.COM}]∕3000
Warfarin elimination is significantly influenced by poly-
morphisms in the CYP2C9 gene, which reduce the ability 
of the CYP2C9 enzyme to metabolise S-warfarin, as well as 
other demographic characteristics such as age, which influ-
ences both liver size and liver blood flow [18]. Earlier, our 
group demonstrated that the variability in INR decline fol-
lowing withdrawal from warfarin therapy is influenced by 
CYP2C9 genetic polymorphism [3]. Our research group also 
more recently demonstrated that the variance in the rate of 
INR decline among patients following warfarin withdrawal 
is affected by polymorphism in CYP2C9 gene (but polymor-
phisms in the VKORC1 gene had no effect), as well as demo-
graphic and clinical factors [3]. A pharmacogenetic-guided 
algorithm was subsequently developed which could predict 
the INR decline for individual patients to reach < 1.5. The 
algorithm includes information on patient genetics (pres-
ence of CYP2C9 double variant genotype), demographic 
(age and weight) and clinical data (index INR, and number 
of comorbidities).
In search of the clinical applicability of this algorithm, 
we tested its accuracy in a second independent cohort of 
patients on stable maintenance therapy withdrawing from a 
short course of warfarin treatment. The results showed that 
the predicted decline in INR on day 5 closely correlated 
with the observed decline in INR value. There was a slight 
over-estimation of the fall in INR (by 0.2 units) in the sub-
group of 70 patients who had an INR check on day 5, and a 
slight under-estimation of INR in the subgroup of 47 patients 
who did not have an INR check on day 5. However, this is 
regarded to be within the expected variability and would not 
be clinically relevant, but would necessitate another INR 
check prior to an invasive procedure.
The two cohorts (algorithm and validation) were signifi-
cantly different in a number of demographics and clinical 
data. The validation cohort included on average younger 
patients with a higher weekly dose of warfarin and greater 
variability in indication for anticoagulation. While these dif-
ferences could affect the present study outcome, such varia-
bility is representative of the wide range of different popula-
tions discontinuing warfarin prior to an invasive procedure.
All but one patient in the validation cohort reached 
INR ≤ 1.5 on or before day 5. Therefore, the results of 
this algorithm validation study are applicable to patients 
that will reach INR of 1.5 or lower on day 5 after warfarin 
discontinuation.
Where INR data on day 5 were missing for some patients 
due to scheduling arrangements, the linear approximation 
model [5] was shown to be highly accurate in predicting 
the INR value in the group of patients with an actual INR 
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check at or very close to day 5. The results of the present 
study are in agreement with the well-recognised associa-
tion of CYP2C9 genotype and age with the decline in INR 
following warfarin cessation, however there are also other 
studies which found no such associations, possibly because 
of missing data [19].
Considering the lack of genotyping facilities in many 
healthcare systems worldwide, this study also looked at the 
predictive ability and accuracy of the algorithm without 
the CYP2C9 genotype component. The results showed that 
the predicted difference in INR decline (i.e. the difference 
between the INR decline predicted from algorithm contain-
ing CYP2C9 genotype and that without genotype informa-
tion) has only a minor effect on the predicted fall in INR and 
would be of limited clinical importance for the patient popu-
lation in this study. The simpler version of the algorithm is 
readily adoptable for routine clinic use to predict the fall in 
INR in individual patients following warfarin cessation with 
or without information on patient CYP2C9 genotype.
In conclusion, a more accurate prediction of the decline 
in INR could reduce the postponement or cancellation of 
planned invasive procedures and therefore be a safer and 
cost-effective way of withdrawing patients from warfarin 
prior to planned invasive procedure compared to the cur-
rent practice. The present algorithm is best tailored to adult 
patients interrupting warfarin for an invasive procedure. 
There is no data available as to whether the algorithm is 
predictive of INR decline in patients who receive any medi-
cation, with excess alcohol intake or suffer from a medical 
condition that may affect warfarin pharmacology or antico-
agulation response. Further study in patient populations dis-
continuing warfarin therapy, either specifically for a surgical 
procedure or for a different reason, with a greater proportion 
of patients remaining above the INR threshold of 1.5 at day 
5 is necessary for the true clinical benefit of this algorithm 
to be appreciated.
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